Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stark Foreign Tax Credit Bill Would Open Fifth Front In Rx Pricing Debate

Executive Summary

Rep. Stark (D-Calif.) will attempt to open a fifth front in the 2000 legislative debate over pharmaceutical pricing with a bill to deny foreign tax credits to companies that charge higher prices in the U.S. than in other industrialized countries.

You may also be interested in...



Drug research tax credits

Rep. Stark's (D-Calif.) drug tax credit bill would deny drug manufacturers a research tax credit for drugs that are sold at a lower price in Organization for Economic Cooperation & Development countries than in the U.S. The bill would not affect foreign tax credits (1"The Pink Sheet" Jan. 3, p. 16). Stark expects to introduce the bill in February

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS035387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel